Meeting
2020 ASCO Virtual Scientific Program
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
Authors
Jonathan E. Rosenberg
Memorial Sloan Kettering Cancer, New York, NY
Jonathan E. Rosenberg , Pablo Gajate , Rafael Morales-Barrera , Jae-Lyun Lee , Andrea Necchi , Nicolas Penel , Vittorina Zagonel , Mitchell Robert Sierecki , Ana-Maria Piciu , Peter Ellinghaus , Randy F. Sweis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03473756
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5014)
DOI
10.1200/JCO.2020.38.15_suppl.5014
Abstract #
5014
Poster Bd #
83
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
First Author: Jonathan E. Rosenberg
Poster
2018 ASCO Annual Meeting
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
First Author: Arjun Vasant Balar
Poster
2024 ASCO Annual Meeting
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.
First Author: Andre Rashad Kydd
Poster
2023 ASCO Annual Meeting
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).
First Author: Chethan Ramamurthy